Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$172.03
pos +0.00
+0.00%
Today's Range: 170.53 - 172.26 | AMGN Avg Daily Volume: 2,836,500
Last Update: 07/29/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 5.98%
Open: $0.00
Previous Close: $171.28
52 Week Range: $130.09 - $181.81
Oustanding Shares: 751,217,078
Market Cap: 128,668,461,120
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 2 2
Hold 10 10 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.34 2.34 2.30 2.30
Latest Dividend: 1.00
Latest Dividend Yield: 2.34%
Dividend Ex-Date: 08/15/16
Price Earnings Ratio: 15.50
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
15.50 18.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.67% 0.33% 57.29%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $2.81 $2.81 $11.35 $12.19
Number of Analysts 10 9 11 12
High Estimate $3.12 $3.12 $11.98 $13.57
Low Estimate $2.66 $2.64 $11.10 $11.40
Prior Year $2.72 $2.61 $10.38 $11.35
Growth Rate (Year over Year) 3.24% 7.75% 9.31% 7.45%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Bullish
Jul 28, 2016 | 7:16 AM EDT
AMGN estimates were raised through 2017, BMO Capital said. Company has strong operating momentum. Outperform rating and new $190 price ...
Stocks remain very unconcerned about rates, despite the odds of a fall increase slightly rising.

I'm Bullish on Biotechs Real Money Pro($)

The market continues to trade lower as we late morning, with Tobira Therapeutics (TBRA) serving as the "disaster du jour" in the small-cap biotech space.
A look at who will be up and who will down this earnings season.
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
Traders and investors should either stand aside or start probing the short side.
Large biotech stocks are still at their cheapest valuations since 2011.

Is Amgen Firming Up? Real Money Pro($)

A fresh rally leg could be on the way if AMGN can remain above the $152 area in the near term. 
Keep cash on hand and be ready for oportunities as they arise.
I prefer a bullish synthetic call.

Columnist Conversations

I wrote positively about Diageo (DEO) on RMP back on June 15th at $100.24. The shares closed last week a...
Market continues to be mixed.  Oil having a rare up day of late, but still up less than 1% on day.  ...
My colleague Suz Smith (RM contributor) often talk about different trade scenarios and structures, importantly...
Thursday's Philadelphia Inquirer reported that the average requested increase for individual health insurance ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.